BioMarin Pharmaceutical Inc. ($BMRN) Stock Forecast: Up 5.2% Today

What is BioMarin Pharmaceutical Inc.?

BioMarin Pharmaceutical Inc. (BMRN) is a biotechnology company specializing in developing therapies for rare genetic diseases. Today, the stock showed a strong bullish movement in the market.

Why is BioMarin Pharmaceutical Inc. going up?

BMRN stock is up 5.2% on Feb 27, 2026 16:01

• Concerns may have initially arisen from the EVP's stock sale, but investors did not seem discouraged by this insider activity.
• The decision to halt the hemophilia gene therapy, Roctavian, due to underwhelming sales could have been seen as a strategic choice to minimize losses and focus on more promising ventures.
• BioMarin's increased efforts in business development amidst rising competition for Voxzogo could have raised investors' optimism about the company's ability to navigate challenges and stay competitive.
• Participation in upcoming investor conferences and a positive Q4 earnings report, surpassing expectations in both earnings and revenue, likely played a role in boosting the positive sentiment surrounding BioMarin's stock today.

BMRN Price Chart

BMRN Technical Analysis

BMRN News

Friberg, Biomarin Pharmaceutical EVP, sells $381k in stock

Gregory R. Friberg, Executive Vice President and Chief R&D Officer at BioMarin Pharmaceutical Inc., sold 6,326 shares of company stock for a total of $381,937. The sale occurred on February 26, 2026, at a weighted average price of $60.3758 per share. Following this transaction, Friberg directly holds 37,578 shares in the company.

https://www.investing.com/news/insider-trading-news/friberg-biomarin-pharmaceutical-evp-sells-381k-in-stock-93CH-4530365

BioMarin shuts down one-and-done hemophilia gene therapy after failing to sell it

BioMarin Pharmaceutical has decided to discontinue its hemophilia gene therapy, Roctavian, due to weak sales, despite initial projections of $2 billion in peak annual sales. The drug only achieved $36 million in sales, leading the company to halt its commercialization efforts. CEO Alexander Hardy confirmed the shutdown in an earnings call, indicating the company's shift away from this specific treatment.

https://www.bizjournals.com/sanfrancisco/news/2026/02/24/hemophilia-a-biomarin-roctavian-gene-therapy.html

BioMarin Leans Into BD As Voxzogo Competition Intensifies

BioMarin is reportedly intensifying its business development efforts as competition for its drug Voxzogo grows. This move suggests the company is looking to strengthen its position in the market amidst challenges from rival pharmaceuticals. The article, published on February 24, 2026, highlights BioMarin's strategic shift.

https://insights.citeline.com/scrip/business/earnings/biomarin-leans-into-bd-as-voxzogo-competition-intensifies-ZHEPCUMI2JHXPKJY3PO2C4EBQQ/

BioMarin to Participate in Four Upcoming Investor Conferences in March

BioMarin Pharmaceutical Inc. announced its management will participate in four upcoming investor conferences in March 2026. These include the TD Cowen 46th Annual Health Care Conference, Leerink 2026 Global Healthcare Conference, Jefferies 2026 Biotech on the Beach Summit, and Barclays 28th Annual Global Healthcare Conference. Management will engage in fireside chats and one-on-one meetings, with webcasts of the fireside chats available on BioMarin's investor relations website.

https://www.prnewswire.com/news-releases/biomarin-to-participate-in-four-upcoming-investor-conferences-in-march-302695288.html

BioMarin: Q4 Earnings Snapshot

BioMarin Pharmaceutical Inc. (BMRN) reported a fourth-quarter loss of $46.6 million, or 24 cents per share, which was better than Wall Street's expectations. The company's adjusted earnings were 46 cents per share, beating analyst estimates of 25 cents. BioMarin also surpassed revenue forecasts, bringing in $874.6 million for the quarter and $3.22 billion for the full year 2025.

https://www.kare11.com/article/syndication/associatedpress/biomarin-q4-earnings-snapshot/616-edebb840-7cee-4fba-b089-575e6a4403d5

Trending Today

Ethereum ($ETH) Crypto Forecast: Down 5.6% Today

Vornado Realty Trust ($VNO) Stock Forecast: Down 5.7% Today

Boston Properties Inc. ($BXP) Stock Forecast: Down 5.5% Today

PNC Financial Services Group Inc. (The) ($PNC) Stock Forecast: Down 5.0% Today

Fastly Inc. ($FSLY) Stock Forecast: Up 5.6% Today

Astera Labs Inc ($ALAB) Stock Forecast: Down 5.0% Today

Capital One Financial Corporation ($COF) Stock Forecast: Down 5.8% Today

Netflix Inc. ($NFLX) Stock Forecast: Up 13.9% Today

GitLab Inc. ($GTLB) Stock Forecast: Down 5.4% Today

Regions Financial Corporation ($RF) Stock Forecast: Down 5.3% Today

BioMarin Pharmaceutical Inc. Price History

13.00.2026 - BMRN Stock was down 5.1%

• The announcement of BioMarin Pharmaceutical's estimated 2025 revenue of $3.2 billion and the strong performance of Voxzogo at $920 million at the recent conference should have been positive news. However, the market may have reacted negatively due to concerns about the company's ability to meet these revenue targets.
• The hiring of Arpit Davé as Chief Digital and Information Officer to accelerate rare disease therapies shows the company's commitment to innovation. However, the market might have interpreted this move as a signal of potential challenges in the current R&D and commercial operations that require urgent attention.
• Despite the outlined growth strategy, pipeline progress, and Amicus integration positioning BioMarin for sustained double-digit compound annual growth rate, investors may have focused on the weak long-term outlook highlighted in the tactical trading analysis. This could have contributed to the bearish movement in the stock.
• The absence of clear long-term support signals and elevated downside risk might have spooked investors, leading to a sell-off of the stock despite the positive developments and revenue projections.

19.11.2025 - BMRN Stock was up 7.7%

• The appointment of Rashmi Ramchandani as the new chief accounting officer brings fresh leadership to BioMarin, potentially signaling positive changes within the company.
• Despite concerns about cost-cutting measures and pipeline shifts, investors seem optimistic about BioMarin's future growth prospects, particularly with the Inozyme acquisition and the focus on rare disease treatments.
• The selling of shares by Hudson Bay Capital Management LP and Bellevue Group AG may have initially raised some eyebrows, but the increased holdings by other institutional investors like Dodge & Cox and Viking Global suggest confidence in BioMarin's long-term potential.
• Overall, the market's bullish response to BioMarin today could be attributed to a combination of new leadership, strategic acquisitions, and investor confidence in the company's ability to navigate through its current transformation phase successfully.

15.11.2025 - BMRN Stock was down 2.1%

• Hudson Bay Capital Management LP, Bellevue Group AG, and other institutional investors have decreased their stakes in BioMarin Pharmaceutical Inc., possibly indicating concerns about the company's immediate performance outlook.
• Despite falling short of quarterly earnings per share (EPS) estimates, BioMarin's positive guidance for FY2025 and ongoing restructuring efforts have generated optimism among investors. This is evidenced by increased holdings from Dodge & Cox, Viking Global, AQR, Geode, Norges Bank, and Boone Capital Management LLC.
• The market's response to the mixed signals of underperforming earnings but promising future projections implies that investors are considering the company's current obstacles against its growth potential and margin expansion through restructuring and late-stage trials.
• The fluctuation in BioMarin's stock price today results from a combination of short-term profit-taking by some investors and long-term confidence stemming from the company's strategic initiatives and advancements in its pipeline.

24.01.2026 - BMRN Stock was down 5.5%

• BioMarin posted strong Q4 revenue surpassing forecasts and a positive full-year 2025 performance. However, the stock witnessed a bearish trend possibly due to falling short of analyst predictions on non-GAAP EPS and adjusted EBITDA.
• The FDA's rejection of BioMarin's gene therapy for hemophilia A, delaying its potential market launch, might have impacted the negative investor sentiment on the company's future revenue prospects.
• An AI analysis indicating a bleak long-term outlook and increased downside risk for BioMarin could have also influenced the downward pressure on the stock.
• In conclusion, the combination of financial performance lagging expectations and regulatory obstacles could have contributed to the bearish movement of BioMarin's stock today.

08.03.2025 - BMRN Stock was down 6.0%

• Today's downward trend in BMRN could be a result of investors taking profits following a period of positive developments and possible overvaluation.
• While the Phase 3 trial results for Palynziq in adolescent patients were encouraging, some investors may have anticipated even better outcomes, leading to selling pressure.
• Comparisons to CSL Limited in terms of valuation might have influenced investor attitudes, prompting some to reconsider their investment allocations in pursuit of perceived better opportunities.
• In conclusion, today's market behavior for BMRN appears to reflect a mix of profit-taking, unmet high expectations, and potential shifts in investor preferences within the sector.

19.01.2026 - BMRN Stock was up 5.1%

• BioMarin's bullish movement today can be attributed to the positive sentiment surrounding the company, as highlighted by analysts and institutional investors increasing their stakes in the company.
• The upcoming conference call to discuss the fourth quarter and full-year 2025 financial results likely generated optimism among investors about the company's performance and future prospects.
• The continued interest from institutional investors, such as Aberdeen Group plc reducing its stake and New York Life Investment Management LLC making a new investment, indicates confidence in BioMarin's long-term growth potential.
• LSV Asset Management's significant increase in stake further reinforces the positive outlook on BioMarin, contributing to the bullish momentum in the stock price.

10.01.2026 - BMRN Stock was up 5.0%

• BMRN saw an upward trend today following positive analyst ratings and price target increases from various firms, including Piper Sandler, Barclays, and Canaccord Genuity.
• Factors such as the impending acquisition of Amicus Therapeutics and the upcoming data release for its experimental therapy INZ-701 have contributed to the positive outlook surrounding BMRN.
• Analysts view BMRN as undervalued with significant growth potential, anticipating revenue escalation and profit margin enhancement in the coming years.
• The company's strategic acquisitions and dedication to rare disease treatments have bolstered investor confidence, driving the bullish market performance.

12.01.2026 - BMRN Stock was up 1.1%

• Despite anticipated Q4 earnings decline, BioMarin Pharmaceutical (BMRN) saw an upward trend, reflecting investor confidence in its long-term prospects.
• Favorable ratings from analysts, adjustments in price targets, and excitement surrounding the impending acquisition of Amicus Therapeutics have contributed to the positive outlook for BMRN.
• The upcoming crucial data release for the experimental therapy INZ-701, designed for treating ENPP1 Deficiency, stands as a significant driver for BioMarin's presence in the rare disease market and likely heightened investor confidence.
• The generally optimistic sentiment towards BMRN, supported by promising forecasts, analyst support, and forthcoming catalysts, has outweighed worries about the projected earnings decline for the quarter.

04.03.2025 - BMRN Stock was down 10.4%

• Despite positive Phase 3 results for Palynziq in lowering blood Phe levels in adolescents, BioMarin's stock saw a bearish trend.
• The market may have reacted negatively due to profit-taking by investors after a recent run-up in the stock price following the positive results.
• Investors might be concerned about the timeline and potential challenges in getting label expansion approval from health authorities despite the promising data.
• The bearish movement could also be influenced by broader market conditions or sector-specific factors impacting biotechnology stocks.

20.01.2025 - BMRN Stock was up 6.3%

• BioMarin's Q4 adjusted EPS exceeding consensus expectations and providing strong sales guidance for 2025 has fueled investor confidence in the company's growth prospects.
• The positive earnings report and future outlook have likely attracted new investors and increased buying interest in the stock.
• The market's reaction indicates that investors are optimistic about BioMarin's ability to deliver on its financial targets and continue its success in developing treatments for rare diseases.

27.01.2026 - BMRN Stock was up 5.2%

• Concerns may have initially arisen from the EVP's stock sale, but investors did not seem discouraged by this insider activity.
• The decision to halt the hemophilia gene therapy, Roctavian, due to underwhelming sales could have been seen as a strategic choice to minimize losses and focus on more promising ventures.
• BioMarin's increased efforts in business development amidst rising competition for Voxzogo could have raised investors' optimism about the company's ability to navigate challenges and stay competitive.
• Participation in upcoming investor conferences and a positive Q4 earnings report, surpassing expectations in both earnings and revenue, likely played a role in boosting the positive sentiment surrounding BioMarin's stock today.

29.09.2025 - BMRN Stock was down 3.3%

• Analysts revised their forecasts for BioMarin Pharmaceutical following lower-than-expected earnings reported for the third quarter.
• Earnings for the quarter were 12 cents per share, missing the analyst consensus estimate of 37 cents per share.
• The unsatisfactory earnings likely shook investor confidence, leading to a bearish movement in the stock price.
• Investors may be worried about the company's future performance and its impact on its pipeline of therapies for rare genetic diseases.